Innovations in American Society of Clinical Oncology practice guideline development

Journal of Clinical Oncology

Volumn 34, Issue 26, 2016, Pages 3213-3220

  Somerfield, Mark R ^a   Bohlke, Kari ^a   Browman, George P ^c,d   Denduluri, Neelima ^b   Einhaus, Kaitlin ^a   Hayes, Daniel F ^e   Khorana, Alok A ^f   Miller, Robert S ^a   Mohile, Supriya G ^g   Oliver, Thomas K ^a   Ortiz, Eduardo ^a   Lyman, Gary H ^h  

^a AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^b US Oncology   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF MICHIGAN   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF ROCHESTER   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHRONIC DISEASE; CLINICAL PRACTICE; LEARNING; MEDICAL SOCIETY; ONCOLOGY; POLICY; PRACTICE GUIDELINE; PRIORITY JOURNAL; WORKFLOW; EVIDENCE BASED MEDICINE; HEALTH CARE DISPARITY; HEALTH CARE QUALITY; HUMAN; MASS COMMUNICATION; ONCOLOGIST; PROGRAM DEVELOPMENT; PROTOCOL COMPLIANCE; STANDARDS; TIME FACTOR; TOTAL QUALITY MANAGEMENT; UNITED STATES; WORKLOAD;

DIFFUSION OF INNOVATION; EVIDENCE-BASED MEDICINE; GUIDELINE ADHERENCE; HEALTHCARE DISPARITIES; HUMANS; MEDICAL ONCOLOGY; ONCOLOGISTS; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; PROGRAM DEVELOPMENT; QUALITY IMPROVEMENT; QUALITY INDICATORS, HEALTH CARE; SOCIETIES, MEDICAL; TIME FACTORS; UNITED STATES; WORKLOAD;

EID: 84989873298     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.68.3524     Document Type: Article

References (31)

1. Institute of Medicine: Clinical practice guidelines we can trust. Washington, DC, National Academies Press, 2011
2. American Society of Clinical Oncology: Recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelinesm J Clin Oncol 12:2471-2508 1994
3. Browman GP, Somerfield MR, Lyman GH, et al: When is good, good enough? Methodological pragmatism for sustainable guideline development. Implement Sci 10:28, 2015
4. Williams GR, Mackenzie A, Magnuson A, et al: Comorbidity in older adults with cancer. J Geriatr Oncol [epub ahead of print on December 22, 2015]
5. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
6. Hershman DL, Wright JD, Lim E, et al: Contraindicated use of bevacizumab and toxicity in elderly patients with cancer. J Clin Oncol 31:3592-3599, 2013
7. Smith TJ, Khatcheressian J, Lyman GH, et al: 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 24:3187-3205, 2006
8. Smith TJ, Bohlke K, Lyman GH, et al: Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 33:3199-3212, 2015
9. Boyd CM, McNabney MK, Correa-de-Araujua, et al: Guiding principles for the care of older adults with multimorbidity: An approach for clinicians - American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity. J Am Geriatr Soc 60:E1-E25, 2012
10. American Society of Clinical Oncology: The state of cancer care in America, 2016: A report by the American Society of Clinical Oncology. J Oncol Pract 12:339-383, 2016
11. Shekelle PG: Updating practice guidelines. JAMA 311:2072-2073, 2014
12. Shojania KG, Sampson M, Ansari MT, et al: How quickly do systematic reviews go out of date? A survival analysis. Ann Intern Med 147:224-233, 2007
13. Newberry SJ, Ahmadzai N, Motala A, et al: Surveillance and Identification of Signals for Updating Systematic Reviews: Implementation and Early Experience. Rockville, MD, AHRQ Methods for Effective Health Care, 2013
14. Lyman GH, Bohlke K, Khorana AA, et al: Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol 33:654-656, 2015
15. Hesketh PJ, Bohlke K, Lyman GH, et al: Antiemetics: American Society of Clinical Oncology focused guideline update. J Clin Oncol 34:381-386, 2016
16. Schünemann HJ, Fretheim A, Oxman AD: Improving the use of research evidence in guideline development: 13. Applicability, transferability and adaptation. Health Res Policy Syst 4:25, 2006
17. Brouwers MC, Kho ME, Browman GP, et al: AGREE II: Advancing guideline development, reporting and evaluation in health care. J Clin Epidemiol 63:1308-1311, 2010
18. Fervers B, Burgers JS, Voellinger R, et al: Guideline adaptation: An approach to enhance efficiency in guideline development and improve utilisation. BMJ Qual Saf 20:228-236, 2011
19. Bower JE, Bak K, Berger A, et al: Screening, assessment, and management of fatigue in adult survivors of cancer: An American Society of Clinical Oncology clinical practice guideline adaptation. J Clin Oncol 32:1840-1850, 2014
20. Denduluri N, Somerfield MR, Eisen A, et al: Selection of optimal adjuvant chemotherapy regimens for human epidermal growth factor receptor 2 (HER2) -negative and adjuvant targeted therapy for HER2-positive breast cancers: An American Society of Clinical Oncology guideline adaptation of the Cancer Care Ontario clinical practice guideline. J Clin Oncol 34:2416-2427, 2016
21. Dillmon M, Goldberg JM, Ramalingam SS, et al: Clinical practice guidelines for cancer care: Utilization and expectations of the practicing oncologist. J Oncol Pract 8:350-353, 2012
22. Shaneyfelt TM, Centor RM: Reassessment of clinical practice guidelines: Go gently into that good night. JAMA 301:868-869, 2009
23. Somerfield MR, Einhaus K, Hagerty KL, et al: American Society of Clinical Oncology clinical practice guidelines: Opportunities and challenges. J Clin Oncol 26:4022-4026, 2008
24. Classen DC, Mermel LA: Specialty society clinical practice guidelines: Time for evolution or revolution? JAMA 314:871-872, 2015
25. Chang SM, Bass EB, Berkman N, et al: Challenges in implementing the Institute of Medicine systematic review standards. Syst Rev 2:69, 2013
26. Van Poznak C, Somerfield MR, Bast RC, et al: Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 33:2695-2704, 2015
27. Harris LN, Ismaila N, McShane LM, et al: Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 34:1134-1150, 2016
28. Simon RM, Paik S, Hayes DF: Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101:1446-1452, 2009
29. Coit DG: NCCN guidelines and quality cancer care: Where have we come from, and where should we be going? J Natl Compr Canc Netw 14:373-377, 2016
30. National Academies of Sciences, Engineering, and Medicine: Biomarker tests for molecularly targeted therapies: Key to unlocking precision medicine. Washington, DC, The National Academies Press, 2016
31. Lyman GH, Moses HL: Biomarker tests for molecularly targeted therapies: Laying the foundation and fulfilling the dream. J Clin Oncol 34:2061-2066, 2016